So far, data from a phase III trial (NCT00045968) using a dendritic cell vaccine (DCVax-L) has indicated that monitoring CTLA-4 expression may predict survival in GBM patients, indicating there may be a role for CTLA-4 as a novel biomarker for treatment response [107, 108]. Here, CTLA4 is linked to glioblastoma.